Cerebrospinal fluid biomarkers in clinical subtypes of early-onset Alzheimer's disease

Dement Geriatr Cogn Disord. 2014;37(5-6):307-14. doi: 10.1159/000355555. Epub 2013 Dec 31.


Background/aims: Accurate diagnosis of sporadic early-onset Alzheimer's disease (EOAD) can be challenging, and cerebrospinal fluid (CSF) biomarkers may assist in this process. We compared CSF indices between three EOAD subtypes: amnestic, logopenic progressive aphasia (LPA), and posterior cortical atrophy (PCA).

Methods: We identified 21 amnestic EOAD, 20 LPA, and 12 PCA patients with CSF data, which included amyloid β1-42 (Aβ42), total tau (t-tau), phospho-tau181 (p-tau), and Aβ42/t-tau index (ATI) levels.

Results: Aβ42 and ATI levels were similar across groups, but t-tau and p-tau levels were significantly lower in PCA patients.

Conclusions: The Aβ42 and ATI data confirm the commonality of the Aβ pathology in EOAD. The lower tau indices in PCA patients may reflect differences in the distribution of neurofibrillary tangles or rates of neurodegeneration.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Alzheimer Disease / cerebrospinal fluid*
  • Alzheimer Disease / classification
  • Amyloid beta-Peptides
  • Biomarkers / cerebrospinal fluid
  • Case-Control Studies
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments
  • Phosphorylation
  • Retrospective Studies
  • tau Proteins


  • Amyloid beta-Peptides
  • Biomarkers
  • MAPT protein, human
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins